Affinity Asset Advisors, LLC Macrogenics Inc Transaction History

Affinity Asset Advisors, LLC

  • $579 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021
SELL
$19.74 - $28.7 $1.58 Million - $2.3 Million
-80,000 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$20.49 - $35.63 $1.13 Million - $1.96 Million
55,000 Added 220.0%
80,000 $2.15 Million
Q1 2021

May 14, 2021
BUY
$18.99 - $33.2 $474,749 - $830,000
25,000 New
25,000 $796,000

Others Institutions Holding MGNX

# of Institutions
132
Shares Held
55.4M
Call Options Held
215K
Put Options Held
238K
View Full List

About MACROGENICS INC

MGNX Quotes by TradingView
  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email